Monteris Medical has secured $35.0 million in funding from investors. The company is the manufacturer of the NeuroBlate® System, a minimally invasive, robotic, laser interstitial thermal therapy (LITT) that utilizes MR-guided surgical ablation technology. This system is specifically designed for use in the brain, offering an advanced surgical tool for the precise ablation of various brain lesions.
The NeuroBlate System addresses a range of critical neurological conditions, including primary and metastatic brain tumors, radiation necrosis, and epileptogenic foci for individuals suffering from drug-resistant epilepsy. This significant capital infusion is intended to support Monteris Medical's strategic growth initiatives, accelerate its commercial expansion, and facilitate the continued advancement of its core technology. The successful completion of this funding round underscores investor confidence in the company's innovative approach to neurosurgery and its established clinical evidence.
The NeuroBlate System is supported by a strong foundation of prospective multi-center clinical evidence, demonstrating its efficacy and patient benefits. Patients undergoing a NeuroBlate procedure have consistently shown short hospital stays, minimal complications, and low hospital readmission rates, highlighting the system's positive impact on patient care and recovery. This evidence base reinforces the value proposition of Monteris Medical's technology in the medical community.
Monteris Medical plans to strategically deploy this investment to expand its market presence and further enhance the capabilities of its NeuroBlate platform. The company aims to continue its mission of providing advanced, minimally invasive treatment options for patients with complex neurological conditions, driving innovation and improving outcomes in the field of neurosurgery globally.
